YouTube Facebook LinkedIn Google+ Twitter Xingrss  

PacBio, Roche Sign Deal for Diagnostics


September 25, 2013 | A Pacific Biosciences-Roche deal announced today has PacBio stock leaping. The deal gives Roche worldwide exclusive rights to in vitro diagnostics products based on PacBio's SMRT technology for $35 million up front and up to $40 million in milestone payments. Motley Fool
Click here to login and leave a comment.  

0 Comments

Add Comment

Text Only 2000 character limit

Page 1 of 1


For reprints and/or copyright permission, please contact  Terry Manning, 781.972.1349 , tmanning@healthtech.com.